[1]孙 玉,张洪海,生守鹏,等.白蛋白-胆红素分级在早期肝细胞癌射频消融中的预后意义 [J].介入放射学杂志,2021,30(05):502-507.
 SUN Yu,ZHANG Honghai,SHENG Shoupeng,et al.Prognostic significance of albumin-bilirubin grading in patients with early hepatocellular carcinoma after radiofrequency ablation treatment[J].journal interventional radiology,2021,30(05):502-507.
点击复制

白蛋白-胆红素分级在早期肝细胞癌射频消融中的预后意义
()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
30
期数:
2021年05
页码:
502-507
栏目:
临床研究
出版日期:
2021-05-25

文章信息/Info

Title:
Prognostic significance of albumin-bilirubin grading in patients with early hepatocellular carcinoma after radiofrequency ablation treatment
作者:
孙 玉 张洪海 生守鹏 袁春旺 崔石昌 郑加生 张永宏
Author(s):
SUN Yu ZHANG Honghai SHENG Shoupeng YUAN ChunwangCUI Shichang ZHENG Jiasheng ZHANG Yonghong.
Minimally-Invasive Interventional Center of Oncology,Affiliated Beijing You’an Hospital, Capital Medical University, Beijing 100069,China
关键词:
【关键词】 癌肝细胞 射频消融 白蛋白-胆红素分级 预后
文献标志码:
A
摘要:
【摘要】 目的 探讨白蛋白- 胆红素(ALBI)分级在接受肝动脉栓塞(TAE)联合射频消融(RFA)治疗的早期HCC患者中预后的意义。方法 选择2006年4月至2010年12月接受TAE联合RFA治疗的HCC患者215例。定期随访,收集患者临床资料数据,Kaplan- Meier法绘制生存曲线,log- rank检验比较生存率,总生存期和无瘤生存期影响因素的单因素及多因素分析采用Cox回归分析。结果 中位随访时间109个月,死亡100例,生存115例,1、2、3、5和10年生存率分别为99.5%、96.7%、92.1%、74%、57.6%。复发165例,1、2、3、5和10年复发率分别22.4%、39.3%、54.2%、69.7%、81.1%。ALBI 1级组患者生存率明显高于2级组患者,差异有显著统计学意义(χ2=9.07,P<0.01)。Cox多因素预后分析显示,年龄、ALBI分级、肿瘤直径是早期HCC患者消融术后长期生存的独立影响因素(P<0.05)。肿瘤直径是早期肝细胞癌患者消融术后无瘤生存期的独立影响因素(P<0.05)。结论 ALBI分级、年龄、肿瘤直径是影响早期HCC RFA术后总生存期的独立危险因素,肿瘤直径是影响无瘤生存期的独立危险因素。

参考文献/References:

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68: 394- 424.
[2] Hung HH, Chiou YY, Hsia CY, et al. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas[J]. Clin Gastroenterol Hepatol, 2011, 9: 79- 86.
[3] Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence- based approach:the ALBI grade[J]. J Clin Oncol, 2015, 33: 550- 558.
[4] Pinato DJ, Sharma R, Allara E, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma[J]. J Hepatol, 2017, 66: 338- 346.
[5] 中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 传染病信息, 2017, 30:111- 127.
[6] 姚红响,陈根生,诸葛英,等. 肝动脉化疗栓塞联合CT引导射频消融序贯治疗中小肝癌的临床应用[J]. 介入放射学杂志,2012, 21:301- 304.
[7] Gui CH, Baey S, D’cruz RT, et al. Trans- arterial chemoembo-lization?+ radiofrequency ablation versus surgical resection in hepatocellular carcinoma :a meta- analysis[J]. Eur J Surg Oncol, 2020, 46:763- 771.
[8] Masatoshi K, Izumi N, Sakamoto M, et al. Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan[J]. Liver Cancer, 2016, 5: 190- 197.
[9] Hiraoka A, Kumada T, Masatoshi K, et al. Albumin- bilirubin (ALBI) grade as part of the evidence- based clinical practice guideline for HCC of the Japan Society of Hepatology:a comparison with the liver damage and Child- Pugh classifi- cations[J]. Liver Cancer, 2017, 6: 204- 215.
[10] Kim YS, Lim HK, Rhim H, et al. Ablation of hepatocellular carcinoma[J]. Best Pract Res Clin Gastroenterol, 2014, 28: 897- 908.
[11] Bruix J, Reig M, Sherman M. Evidence- based diagnosis, staging, and treatment of patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 150: 835- 853.
[12] Yau T, Tang VY, Yao TJ, et al. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma[J]. Gastroenterology, 2014, 146: 1691- 1700.
[13] Masatoshi K, Trevisani F, Abou- Alfa GK, et al. Hepatocellular carcinoma:therapeutic guidelines and medical treatment[J]. Liver Cancer, 2017, 6: 16- 26.
[14] 张争运,张国梁,万 霖,等. ALBI分级对反复行TACE治疗肝细胞癌患者预后评估的价值[J]. 肿瘤, 2019, 39: 722- 729.
[15] Zou H, Yang X, Li QL, et al. A comparative study of albumin- bilirubin score with Child- Pugh score, model for end- stage liver disease score and indocyanine green R15 in predicting posthepa- tectomy liver failure for hepatocellular carcinoma patients[J]. Dig Dis, 2018, 36: 236- 243.
[16] Oh IS, Sinn DH, Kang TW, et al. Liver function assessment using albumin- bilirubin grade for patients with very early- stage hepatocellular carcinoma treated with radiofrequency ablation[J]. Dig Dis Sci, 2017, 62: 3235- 3242.
[17] Chen PC, Chiu NC, Su CW, et al. Albumin- bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy[J]. J Chin Med Assoc, 2019, 82: 2- 10.
[18] Bag rsakci E, Sahin E, Atabey N, et al. Role of albumin in growth inhibition in hepatocellular carcinoma[J]. Oncology, 2017, 93: 136- 142.
[19] Shim JH, Jun MJ, Han S, et al. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma[J]. Ann Surg, 2015, 261: 939- 946.
[20] Du ZG, Wei YG, Chen KF, et al. Risk factors associated with early and late recurrence after curative resection of hepatocellular carcinoma: a single institution’s experience with 398 consecutive patients[J]. Hepatobiliary Pancreat Dis Int, 2014, 13: 153- 161.
[21] Albillos A, Lario M, Alvarez- Mon M. Cirrhosis- associated immune dysfunction: distinctive features and clinical relevance[J]. J Hepatol, 2014, 61: 1385- 1396.
[22] Ma S, Ding M, Li J, et al. Ultrasound- guided percutaneous microwave ablation for hepatocellular carcinoma: clinical outcomes and prognostic factors[J]. J Cancer Res Clin Oncol, 2017, 143: 131- 142.

相似文献/References:

[1]申淑群,杨业发,葛乃建,等.肝癌破裂出血的介入与外科手术疗效评价[J].介入放射学杂志,2010,(07):544.
 SHEN Shuqun,YANG Yefa,GE Naijian,et al.Evaluation of interventional and surgical treatments for the hemorrhage of ruptured hepatocellular carcinoma[J].journal interventional radiology,2010,(05):544.
[2]郑加生,崔雄伟,禹纪红.自发性肝癌破裂出血的急诊动脉栓塞治疗[J].介入放射学杂志,2006,(04):228.
 ZHANG Jia-sheng,CUI Xiong-wei,YU Ji-hong,et al.Emergency transcatheter arterial embolization for beeding of hepatocellular carcinoma spontaneous rupture[J].journal interventional radiology,2006,(05):228.
[3]李强,曾从俊,王莺.化疗栓塞联合质子放射治疗肝癌合并门脉主干癌栓的临床应用[J].介入放射学杂志,2009,(04):278.
 LI Qiang,ZENG Congjun,WANG Ying.Interventional chemoembolization combined with proton radiotherapy for the treatment of hepatocellular carcinoma accompanied with portal cancerous thrombus[J].journal interventional radiology,2009,(05):278.
[4]张长青,吴伟岗,曾志雄,等.肝动脉化疗栓塞及注射~(32)P-胶体、无水乙醇综合序贯介入治疗原发性肝癌疗效分析[J].介入放射学杂志,2000,(01):22.
[5]经 翔,丁建民,王彦冬,等. 射频消融和微波消融治疗肝癌的比较[J].介入放射学杂志,2014,(04):306.
 JING Xiang,DING Jian? min,WANG Yan? dong,et al. Ultrasound-guided percutaneous radiofrequency ablation and microwave ablation for the treatment of hepatocellular carcinoma: a comparison study[J].journal interventional radiology,2014,(05):306.
[6]钱 晟,刘 嵘,王建华,等.栓塞肝动脉-门静脉瘘在TACE联合门静脉支架治疗肝癌伴门静脉癌栓中的临床意义[J].介入放射学杂志,2015,(04):306.
 QIAN Sheng,LIU Rong,WANG Jian hua,et al.Embolization of hepatic arterio portal shunt in patients with HCC complicated by portal vein tumor thrombus treated with TACE combined with portal vein stenting: its clinical significance[J].journal interventional radiology,2015,(05):306.
[7]刘秋松,梅雀林,李彦豪,等.化疗栓塞治疗肝癌合并肝动-静脉分流的生存预后因素分析[J].介入放射学杂志,2015,(12):1056.
 LIU Qiu-song,MEI Que-lin,LI Yan-hao,et al.Interventional chemoembolization for the treatment of hepatocellular carcinoma associated with hepatic arteriovenous shunt: analysis of survival prognostic factors[J].journal interventional radiology,2015,(05):1056.
[8]刘秋松,梅雀林,何晓峰,等.索拉非尼联合PVA微粒化疗栓塞治疗肝癌并肝动-静脉分流的疗效及预后分析[J].介入放射学杂志,2016,(04):320.
 LIU Qiu- song,MEI Que- lin,HE Xiao- feng,et al.Sorafenib plus percutaneous chemoembolization with polyvinyl alcohol for hepatocellular carcinoma complicated by hepatic arteriovenous shunts: analysis of curative effect and prognosis[J].journal interventional radiology,2016,(05):320.
[9]黄 芳,龚环宇,熊正平.雷替曲塞联合奥沙利铂TACE治疗BCLC B/C期肝细胞癌的安全性及疗效[J].介入放射学杂志,2018,27(01):76.
 HUANG Fang,GONG Huanyu,XIONG Zhengping.The safety and efficacy of raltitrexed combined with oxaliplatin in TACE treatment for BCLC B/C hepatocellular carcinomas[J].journal interventional radiology,2018,27(05):76.
[10]戴高乐,罗万权,赵许亚,等.眼部Merkel细胞癌介入治疗1例[J].介入放射学杂志,2020,29(10):1060.
 DAI Gaole,LUO Wanquan,ZHAO Xuya,et al.Successful interventional treatment of Merkel cell carcinoma located at the lateral canthus of left eye: report of one case[J].journal interventional radiology,2020,29(05):1060.
[11]周卫忠,刘 圣,杨正强,等.氰基丙烯酸酯胶栓塞原发性肝细胞癌合并重度肝动脉门静脉瘘12例疗效分析[J].介入放射学杂志,2013,(08):641.
 ZHOU Wei? zhong,LIU Sheng,YANG Zheng? qiang,et al. Transarterial embolization therapy with cyanoacrylate for severe arterioportal shunt associated with hepatocellular carcinoma[J].journal interventional radiology,2013,(05):641.
[12]郑家平,邵国良,罗 君,等. 索拉非尼治疗中晚期肝细胞癌安全性和预后因素分析[J].介入放射学杂志,2014,(03):222.
 ZHENG Jia? ping,SHAO Guo? liang,LUO Jun,et al. Sorafenib for the treatment of intermediate?蛳 advanced hepatocellular carcinomas: its safety and prognostic factors[J].journal interventional radiology,2014,(05):222.
[13]万豪光,许 伟,徐 浩,等. 经导管化疗栓塞联合经皮微波消融治疗中晚期肝癌64例的预后分析[J].介入放射学杂志,2014,(06):477.
 WAN Hao- guang,XU Wei,XU Hao,et al. Transcatheter arterial chemoembolization combined with percutaneous microwave ablation for the treatment of intermediate- advanced hepatocellular carcinoma: analysis of prognostic factors in 64 cases[J].journal interventional radiology,2014,(05):477.
[14]涂文辉,罗剑钧,刘清欣,等.原发性肝癌伴门静脉主干癌栓患者存活超5年1例并文献复习[J].介入放射学杂志,2015,(12):1101.
 TU Wen- hui,LUO Jian- jun,LIU Qing- xin,et al.Primary hepatocellular carcinoma associated with portal vein tumor thrombus: report of one case with survival over 5 years and review of literature [J].journal interventional radiology,2015,(05):1101.
[15]李 卿,梁 斌.化疗栓塞联合替拉扎明治疗肝癌的研究进展[J].介入放射学杂志,2021,30(08):846.
 LI Qing,LIANG Bin..Research progress in the treatment of hepatocellular carcinoma with chemoembolization combined with tirapazamine[J].journal interventional radiology,2021,30(05):846.

备注/Memo

备注/Memo:
(收稿日期:2020- 02- 19)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2021-05-20